Stocktoria

Zymeworks Inc. ZYME

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-06-24 · LEI

Zymeworks Inc. statistics & valuation

Market cap$1.6B
P / S15.5×
P / B6.1×
Net margin-76.6%
Return on equity-30.2%
FCF margin-32.6%
Return on capital-30.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-794.00% 30.10% -156.10% -160.80% -76.60% 20212022202320242025
Gross margin (%)
20212022202320242025
Operating margin (%)
-808.20% 31.60% -181.60% -179.70% -87.30% 20212022202320242025
Return on equity (%)
-85.00% 25.20% -25.50% -36.20% -30.20% 20212022202320242025
Shares outstanding
52.1M 65.2M 70.1M 75.9M 75.4M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-54.40% 19.20% -20.40% -26.50% -23.40% 20212022202320242025
Free cash flow margin (%)
-767.80% 33.00% -158.90% -146.80% -32.60% 20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$4.61 $1.90 -$1.72 -$1.62 -$1.08 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Operating margin-87.3%-179.7%-181.6%31.6%-808.2%
Net margin-76.6%-160.8%-156.1%30.1%-794.0%
FCF margin-32.6%-146.8%-158.9%33.0%-767.8%
Return on assets-23.4%-26.5%-20.4%19.2%-54.4%
Return on equity-30.2%-36.2%-25.5%25.2%-85.0%
Current ratio5.883.407.415.704.01

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.